

Aspiring to be a Global Leader in Women's Health



Her health,
our mission

partnering@heranova.com

Forward Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Global Leadership Team

Seasoned women's health global leaders and serial entrepreneurs



Farideh Bischoff, PhD

CMO and Co-founder

- > 25 years of expertise in developing non-invasive clinical assays for various women's health conditions
- > Executive and serial entrepreneur (FreMon Scientific, Biosystems, Biocept)
- > Professor at Baylor College of Medicine



Jonathan Y. Zhao, PhD, MBA

CEO and Co-founder

- > Serial entrepreneur, co-founder and Chairman of Transcenta Holding (6628.HK)
- > Venture Partner at Lilly Asia Ventures
- > Executive Director of Global Commercial at Amgen



Marcel van Duin, PhD

CSO

- > Seasoned global R&D leader in Women's Health space
- > Former CSO of Organon, VP of R&D at Ferring, Head of WH Discovery franchise at Merck
- > Decades of experience in endometriosis, infertility, obstetrics and other WH indications



John Fair

CBO

- > Senior executive specializing in emerging and specialty women's health drug and device
- > Strategic transactions with leading women's healthcare MNC
- > Equity and non-dilutive financings raising >\$300 Mn



Supported by World-Class Scientific Advisors



Prof. Dr. Joe Leigh Simpson

Professor, Herbert Wertheim College of Medicine

- Former president of the ASRM & IFFS
- Chairman of OB/GYN at Baylor College of Medicine
- US National Academy of Medicine, Academy of Sciences



Krina Zondervan, PhD

Professor, Head of Nuffield Dept. of Women's & Reproductive Health, Oxford University

- Genomic Epidemiology, co-director Endometriosis care-centre
- Previously led global endometriosis initiative to develop standardized deep phenotyping tools and sample collection protocols



Dr. Denny Sakkas

Scientific Director, Boston IVF

- Associate Prof OB/GYN & Reproductive Science at Yale University
- Editorial Board of 5 leading journals in reproductive medicine
- CSO at Molecular Biometrics



Dr. Antoinette M. Marengo-Barbick

Chief Medical Officer, PPF Pacific Southwest

- Executive Council for District IX, ACOG
- Lieutenant Commander, United States Navy, Staff OB/GYN
- Residency Program Director, UC Irvine and Naval Medical Center



Dr. Will Dere

Internal Medicine, University of Utah

- International Chief Medical Officer at Amgen
- VP of Endocrine, Bone and General Medicine at Eli Lilly



Prof. Dr. Aleksandar Rajkovic

Professor, Pathology and OBGYN and Reproductive Sciences, UCSF

- Chief Genomics Officer, Medical Director of the Center for Genetic and Genomic Medicine (CGGM)
- Stuart Lindsay Distinguished Professor in Experimental Pathology



Dr. Ronald F. Feinberg

RADfertility Chief Medical Officer/Director of IVF Programs

- Reproductive Endocrinology/Infertility and OB/GYN
- MD/PhD: University of Pennsylvania, Philadelphia, PA



Prof. Dr. Ernest Ng

Professor, Department of OB/GYN, University of Hong Kong

- Director of OB/GYN at Queen Mary Hospital
- Board member of International Society of Gynecological Endocrinology (ISGE), Hong Kong OB/GYN Association

Endometriosis

A Condition that Impact Millions of Women

01

About **10% of reproductive-age** women and 20-50% of infertile women have endometriosis.

02

The condition is defined by the growth/spread of the endometrium-like tissue outside of the uterus.

03


The **pathogenesis is unclear**, and the clinical presentation varies widely, ranging from asymptomatic to severe; symptoms may not correlate with the stage of the condition.

04

Symptoms can include **severe pain**, dysmenorrhea, dyspareunia, dysuria, **infertility**, and fatigue.

05

New therapeutic options are needed, and a non-invasive test can support new pharmaceutical R&D in endometriosis. Currently, hormonal therapy controls symptoms in some women whereas others require surgery.



Pain-sensing nerves and immune cells work together to wreak havoc in **endometriosis**, a painful condition that affects an estimated **190 million women and girls of reproductive age**.

The Problem

The **Diagnostic Gold Standard is Surgery** – Which is **Costly, Invasive,** and Unnecessary in ~50% of Patients



Utilizing imaging (**Transvaginal Ultrasound & MRI**) for diagnosis is often **operator dependent** and **less effective when endometriosis tissue is less than 5 mm** or on the surface of an organ (superficial endometriosis), which is **the most common type of endometriosis**.



Diagnostic confirmation is typically achieved through **laparoscopy (a surgical procedure)**, an often times painful in-patient procedure that can last as long as six hours, leave a woman scarred and takes an average of 6 to 12 weeks for the tissue to heal.

- ✔ ~33% of all laparoscopic surgeries are for Endometriosis
- ✔ Each laparoscopic surgical intervention costs the healthcare system anywhere from **\$10,000 to \$25,000**.
Endometriosis costs the healthcare system **~\$119 billion annually - a major cost driver is surgery.**
- ✔ Data suggests that as many as **50% of patients undergoing the procedure may not have endometriosis.**



1. <https://www.webmd.com/women/endometriosis/laparoscopic-surgery>;
2. <https://pelvicpainrehab.com/>
3. <https://obgyn.onlinelibrary.wiley.com/doi/10.1002/uog.24892>
4. FERTILITY AND STERILITY VOL. 82, NO. 4, OCTOBER 2004
5. <https://www.cnn.com/2016/05/19/this-neglected-disease-is-a-hidden-drain-on-womens-success.html>

The Solution

HerResolve™



HerResolve is the only non-invasive, blood-based test that diagnoses endometriosis in women experiencing symptoms such as pelvic pain, painful periods, and dysmenorrhea and considering undergoing surgery for diagnostic confirmation




HerResolve is a simple blood test that provides accurate information about the “**presence or absence**” of endometriosis. By eliminating the need for exploratory surgery when the disease is not present, it offers women a safer, non-invasive diagnostic alternative to laparoscopy. Additionally, when disease is present, HerResolve can empower doctors to take the *next best action* to improve patient outcomes.



HerResolve demonstrates superior performance in validation studies and **is intended to decrease medically unnecessary exploratory procedures and guide personalized treatment.**

HerResolve™ Provides Distinct and Reproducible Results

5 of the miRNA biomarkers show very distinct and reproducible expression levels differentially expressed in **endometriosis patients (gold)** as compared to normal **healthy controls (green)**




HerResolve™ Highlights Accuracy in Multiple Models



Leveraging the power of **AI and machine learning**, the Heranova team trained and tested several models comparing patients to patient controls. The model to the right highlights superior results with greater than 90% in both sensitivity and accuracy

*Patient vs Patient Control
Model Performance Example*



Performance	HerResolve ¹ <i>Estimated</i>	Surgery with Histology ²	Surgery without Histology ²
Sensitivity	>90%	90%	82.3%
Accuracy	>90%	77%	77%


Surgery is the current "gold" standard of care for diagnosing endometriosis

1. Data on file
 2. Gratton, S et al. "Diagnosis of Endometriosis at Laparoscopy: A Validation Study Comparing Surgeon Visualization with Histologic Findings." Journal of Obstetrics and Gynaecology Canada, 2022, Volume 44, Issue 2, 135 – 141

HerResolve™

Potentially the 1st FDA 510(k) cleared non-invasive diagnostic test for endometriosis

Key Milestone Timelines*	2024		2025	
	Q3	Q4	1H	2H



- Planned Publications**
- 1 Innovations
 - 2 ACOG / Abstract
 - 3 US Validation Publication (Targeting Top-Tier Journal)

HerResolve™ - US Commercial Potential

First-in-class innovation with estimated peak annual sales potential >\$500M USD

Serviceable Obtainable Market (SOM)

01 Endometriosis Surgery (OB/GYN, IVF/REI)

02 Endometriosis Symptoms (OB/GYN + Pediatricians, Family Practice)

03 The Endometriosis market will experience double-digit growth through 2030*

04 In addition to becoming a powerful standalone *predictive tool*, **HerResolve** can become a companion diagnostic (CDx) for current and planned prescription (Rx) endometriosis products.

SOM
~13 Million
Patients


- Pelvic Pain (Adjacent symptoms)
- Endometriosis (Earlier stage)
- Endometriosis (IVF/Fertility)
- Endometriosis (Late Stage/Surgical)

HerResolve
>\$500M

10.6%

*The endometriosis market is projected to grow at a CAGR between 2020 and 2030

Anticipated approval of several pipeline agents during the 2020–2030 forecast period will drive strong growth across the seven major markets, namely the US, 5EU (France, Germany, Italy, Spain and the UK) and Japan — according to GlobalData's recent Endometriosis: Global Drug Forecast and Market Analysis to 2030 report. The endometriosis market is expected to grow from \$1.06bn in 2020 to \$2.91bn in 2030 at a combined annual growth rate (CAGR) of 10.6% across the seven major markets.



Thank you

For partnering inquiries, please email:

partnering@heranova.com